CoChat

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine

Allgulander, Christer, Mangano, Richard, Zhang, Jun, Dahl, Alv A., Lepola, Ulla, Sjödin, Ingemar, Emilien, Gerard · 2004 · Human Psychopharmacology: Clinical and Experimental
Cited by 111

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short‐term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (n = 434) were randomized to receive capsules of venlafaxine ER 75 mg to 225 mg/day, paroxetine 20 mg to 50 mg/day, or placebo for 12 weeks. The primary efficacy variable was the Liebowitz social anxiety scale total score. Secondary efficacy variables included the patient‐rated social phobia inventory and the proportion of responders in each group (a responder was defined as having a clinical global impression‐improvement score of 1 or 2). Treatment with venlafaxine ER was associated with significantly greater improvement than treatment with placebo for all primary and secondary efficacy variables (p < 0.05). No significant differences in primary or secondary efficacy variables were observed between the venlafaxine ER and paroxetine groups. The week 12 response rates were 69%, 66% and 36% for the venlafaxine ER, paroxetine and placebo groups, respectively. Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well‐tolerated drug treatment for SAD. Copyright © 2004 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hup.602

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 43

  1. 10.1111/j.1600-0447.1999.tb10845.x · DOI · Paper page
  2. 10.1097/00004850-199907000-00006 · DOI · Paper page
  3. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders
  4. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
  5. 10.1192/bjp.175.2.120 · DOI · Paper page
  6. Ballenger JC, 1999, Clinical guidelines for establishing remission in patients with depression and anxiety, J Clin Psychiatry, 60, 29
  7. Ballenger JC, 2001, Treatment of anxiety disorders to remission, J Clin Psychiatry, 62, 5
  8. Ballenger JC, 1998, Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety, J Clin Psychiatry, 59, 60
  9. 10.4088/JCP.v60n0805 · DOI · Paper page
  10. 10.1001/archpsyc.1994.03950120047008 · DOI · Paper page
  11. 10.1016/S0165-0327(97)00109-2 · DOI
  12. FurmarkT.2000.Social Phobia. From Epidemiology to Brain Function. Dissertation the Faculty of Social Sciences Uppsala University Sweden.
  13. 10.1001/jama.283.23.3082 · DOI · Paper page
  14. Guy W, 1976, ECDEU Assessment Manual for Psychopharmacology
  15. 10.1016/S0924-977X(03)92184-5 · doi:10.1016/s0924-977x(03)92184-5
  16. 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  17. 10.1016/S0006-3223(01)01183-0 · DOI · Paper page
  18. 10.1016/S0165-1781(03)00071-4 · DOI
  19. Judd LL, 1994, Social phobia: a clinical overview, J Clin Psychiatry, 55, 5
  20. 10.1176/appi.ajp.158.12.1999 · DOI · Paper page
  21. Kelsey JE, 1995, Venlafaxine in social phobia, Psychopharmacol Bull, 31, 767
  22. 10.1097/00004714-199802000-00004 · DOI · Paper page
  23. 10.1002/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
  24. Liebowitz MR, 2002, Venlafaxine XR in generalized social anxiety disorder, Int J Neuropsychopharmacol, 5, S211
  25. Liebowitz MR, 2002, Efficacy of venlafaxine XR in generalized social anxiety disorder, Int J Neuropsychopharmacol, 5, S211
  26. Lipman RS, 1982, Differentiating anxiety and depression in anxiety disorders: use of rating scales, Psychopharmacol Bull, 18, 69
  27. 10.1046/j.1365-2796.2001.00881.x · DOI
  28. 10.1016/S0006-3223(01)01309-9 · DOI · Paper page
  29. Morrow JD, 2003, Pentagastrin‐induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol, J Psychiatry Neurosci, 28, 127
  30. 10.1097/00005053-196901000-00010 · DOI · Paper page
  31. 10.1176/ajp.145.5.590 · DOI · Paper page
  32. 10.2165/00019053-199304050-00006 · DOI · Paper page
  33. 10.1176/appi.ajp.157.6.968 · DOI · Paper page
  34. Sheehan DV, 1998, The Mini‐International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10, J Clin Psychiatry, 59, 22
  35. 10.1111/j.1600-0447.1996.tb10624.x · doi:10.1111/j.1600-0447.1996.tb10624.x
  36. 10.4088/JCP.v60n0105 · DOI · Paper page
  37. 10.1176/appi.ps.53.6.714 · DOI · Paper page
  38. 10.1001/archpsyc.59.12.1111 · DOI · Paper page
  39. 10.1097/00004714-199606000-00005 · DOI · Paper page
  40. 10.1176/ajp.156.5.756 · DOI · Paper page
  41. 10.1001/jama.280.8.708 · DOI · Paper page
  42. 10.1192/bjp.178.3.234 · DOI · Paper page
  43. 10.1176/appi.ajp.158.2.275 · DOI · Paper page

Cited by

Metadata

Authors
Allgulander, C., Mangano, R., Zhang, J., Dahl, A. A., Lepola, U., Sjödin, I., & Emilien, G.
Venue
Human Psychopharmacology: Clinical and Experimental
Publisher
Wiley
Published
2004-06-15
Volume
19
Issue
6
Pages
387-396
ISSN
  • 0885-6222 (ISSN-L)
  • 1099-1077
OpenAlex
W1964802747
Cited by
111
References
9
FWCI
13.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.